Director's Dealing • Jun 18, 2021
Director's Dealing
Open in ViewerOpens in native device viewer
National Storage Mechanism | Additional information ![]()
RNS Number : 3148C
Diaceutics PLC
18 June 2021
18 June 2021
Diaceutics PLC
("Diaceutics" or "the Company")
Purchase of Shares and PDMR Shareholding
Diaceutics PLC, (AIM: DXRX), the diagnostic commercialisation company for precision testing announces that on 17 June 2021, Deborah Davis, the Chair of Diaceutics, purchased a total of 27,000 ordinary shares of £0.002 each in the Company ("Ordinary Shares"). Of these, 20,000 were purchased at a price of 130 pence per Ordinary Share, and 7,000 at a price of 128 pence per Ordinary Share. As a result of the purchase, Deborah's shareholding is 27,000 Ordinary Shares, representing approximately 0.03% of the Company's issued share capital.
Enquiries:
| Diaceutics PLC | |
| Philip White, Chief Financial Officer | Via Alma PR |
| Stifel Nicolaus Europe Limited (Nomad & Broker) | Tel: +44 (0)20 7710 7600 |
| Ben Maddison | |
| Stewart Wallace | |
| Nick Adams | |
| Alma PR | Tel: +44(0)20 3405 0205 |
| Caroline Forde | [email protected] |
| Robyn Fisher | |
| Kieran Breheny |
About Diaceutics
At Diaceutics we believe that every patient should have access to the right treatment at the right time. We provide the world's leading pharmaceutical companies with an end-to-end solution for the launch of precision medicine diagnostics enabled by DXRX - The Diagnostic Network®.
DXRX is the world's first diagnostic commercialisation platform for precision medicine, integrating multiple pipelines of real-world diagnostic testing data from a global network of laboratories.
| Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014 | ||||||
| 1 | Details of the person discharging managerial responsibilities/person closely associated | |||||
| a. | Name | Deborah Davis | ||||
| 2 | Reason for notification | |||||
| a. | Position/Status | Chair | ||||
| b. | Initial notification/ Amendment |
Initial | ||||
| 3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
| a. | Name | Diaceutics PLC | ||||
| b. | LEI | 213800VEWQBB39ZB8J81 | ||||
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||
| a. | Description of the financial instrument, type of instrument Identification Code |
Ordinary shares of £0.002 each ISIN: GB00BJQTGV64 |
||||
| b. | Nature of the transaction | Purchase | ||||
| c. | Price(s) and volume(s) | Share purchase: | ||||
| Price(s) | Volume(s) | |||||
| 130 p | 20,000 | |||||
| 128 p | 7,000 | |||||
| d. | Date of the transaction | 17 June 2021 | ||||
| e. | Place of the transaction | AIM Market of the London Stock Exchange |
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
DSHFLFSARTIDLIL
Building tools?
Free accounts include 100 API calls/year for testing.
Have a question? We'll get back to you promptly.